Jonathan Rubin - 23 Feb 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: SVP, Chief Medical Officer
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 23 Feb 2024
Net transactions value: -$16,477
Form type: 4
Filing time: 27 Feb 2024, 17:00:51 UTC
Previous filing: 26 Feb 2024
Next filing: 26 Dec 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Award	$0	+1,250	+32%	$0.000000	5,208	23 Feb 2024	Direct
transaction	SUPN	Common Stock	Tax liability	$16,477	-567	-11%	$29.06	4,641	23 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Restricted Stock Unit	Disposed to Issuer	$0	-1,250	-25%	$0.000000	3,750	23 Feb 2024	Common Stock	1,250		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
F2	Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F3	These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.